# allied Joint Event on

International Conference on

### **OBESITY AND WEIGHT MANAGEMENT**

&

International Conference on

## **VACCINES AND IMMUNOLOGY**

#### June 28-29, 2018 | Amsterdam, Netherlands

Asian J Biomed Pharmaceut Sci 2018, Volume 8 | DOI: 10.4066/2249-622X-C1-003

### OUTCOME OF PREDNISOLONE TREATMENT OF IDIOPATHIC MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS ADULT PATIENTS IN OMDURMAN MILITARY HOSPITAL KHARTOUM SUDAN

#### Altigani Aljafari

University of California, USA

**Background:** Membranoproliferative glomerulonephritis (MPGN) is a type of glomerulonephritis caused by deposits in the kidney glomerular mesangial and basement membrane thickening, activating complement and damaging the glomeruli. (MPGN) classified to three types according to location of deposits and based on etiology categorized to secondary and idiopathic.

**Objective:** The aim of the study is to find the outcome of treatment (remission, partial remission, relapse and progress to end stage renal disease) of idiopathic membranoproliferative glomerulonephritis, among adult Sudanese patients presenting to Omdurman Military Hospital, Renal Unit.

Materials & Methods: A retrospective study of patients with idiopathic MPGN followed up at the clinic. 45 patients with no identifiable cause of MPGN were included. Idiopathic (MPGN) patients who have high renal profile or nephrotic range treated by three doses of methylprednisolone 0.5 g intravenous in three consecutive days and of corticosteroid tabs (0.5-1mg/kg/day), slowly withdrawn according to the patient response indicated by spot urine test.

**Results:** Out of 45 patients the following treatment outcomes were observed, (remission, partial remission, relapsed, and progressed to (ESRD), (44%, 16%, 18% and 22%) respectively.

Conclusions: In comparison to the similar studies, the remission rate is comparable, but the renal survival rate is different.

dr.tigani@live.com